Verrica to present YCANTH and VP-315 data at two dermatology meetings

Post-hoc Phase 3 data show YCANTH cleared molluscum in over half of long-duration patients, while VP-315 showed abscopal-like activity in untreated

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A bright medical treatment room featuring a silver laser device poised over a white table, an examination bed with a blue sheet, and blurred medical equipment and white cabinets with shelves in the background.

Verrica Pharmaceuticals will present two posters at the 27th Annual Las Vegas Dermatology Seminar (17–20 September) and Maui Derm NP+PA Fall 2026 (16–19 September), covering its approved molluscum therapy YCANTH (VP-102) and its investigational oncolytic peptide VP-315 in basal cell carcinoma.

The YCANTH data, disclosed publicly for the first time, come from a post-hoc pooled analysis of two completed Phase 3 trials. The analysis was designed to test whether the duration of molluscum infection before treatment affects clinical response, a practical concern for clinicians deciding whether to treat or monitor patients with established disease.

YCANTH: clearance rates hold regardless of disease history

The findings indicate that treatment benefit is not materially diminished by longer disease duration. Among patients with molluscum for 12 months or less, 48.9% of those receiving YCANTH achieved complete clearance of all lesions at Day 84, against 16.7% in the vehicle arm (p<0.0001). In patients with disease lasting more than 12 months, the YCANTH complete-clearance rate was 58.8%, compared with 5.0% in the vehicle group (p<0.0001). Median lesion-count reduction reached 100% with YCANTH in both duration groups, versus roughly 48–51% with vehicle.

The company frames these results as support for active treatment over the "watch and wait" approach that was common before YCANTH became the first and only FDA-approved, healthcare professional-administered therapy for molluscum in patients aged two years and older. Molluscum contagiosum affects an estimated six million people in the United States, predominantly children, and until YCANTH's approval, clinicians had no approved option to offer families seeking intervention.

Chief medical officer Noah Rosenberg noted that the data give "clinicians confidence to treat their patients with YCANTH at any time after diagnosis," a message likely aimed at expanding uptake among practitioners who may have been reserving treatment for recently diagnosed cases.

VP-315 abscopal signals in basal cell carcinoma

The second poster, an encore of data first presented at the 2026 Society for Investigative Dermatology Annual Meeting, describes an exploratory analysis of VP-315 in patients with basal cell carcinoma. Verrica observed mean tumour size reduction in 14 untreated, non-target lesions following intratumoral injection of separate target lesions, with three of those 14 achieving complete histological clearance. This pattern is consistent with an abscopal-like immune response, in which local treatment triggers systemic anti-tumour activity at distant sites.

VP-315, generically known as ruxotemitide, is an oncolytic peptide designed to induce immunogenic cell death and stimulate T-cell responses against a broad spectrum of tumour antigens. It is administered intratumorally and is being developed as a potential non-surgical option for non-metastatic basal cell and squamous cell carcinomas. Verrica holds a worldwide licence from Lytix Biopharma to develop and commercialise the asset in dermatological oncology.

Competitive and regulatory context

The dermatology oncology space, particularly for locally advanced basal cell carcinoma, is already served by hedgehog pathway inhibitors such as vismodegib and sonidegib, which carry significant tolerability limitations. An intratumoral immunotherapy capable of generating off-lesion responses could address a meaningful clinical gap, particularly for patients with multiple or recurrent tumours. However, VP-315 remains in Phase 2, and the abscopal data reported here are exploratory; the company has not yet outlined a Phase 3 design or regulatory submission timeline for the asset.

For YCANTH, the competitive dynamics are more straightforward: it holds first-mover advantage as the only approved prescription option for molluscum, and publication of further subgroup analyses is a standard commercial strategy to build prescriber confidence and reinforce guideline positioning. Verrica is also studying YCANTH in common warts, both in the United States and under a Japanese approval programme, providing a second growth vector for the franchise.

Sector

Topic

Geography